The problem applies to Abbott’s Libre 3 and Libre 3 Plus sensors. The company said it has received reports of 736 severe adverse events and seven deaths.
Medical Device Network on MSN
Abbott issues correction over incorrect FreeStyle Libre sensor readings
The correction relates to around three million sensors used in Abbott’s FreeStyle Libre 3 and Libre 3 Plus CGMs in the US.
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...
Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
The correction is one of the largest in Abbott's recent continuous glucose monitor business, which dominates the global ...
Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.
Abbot has issued a medical device correction for some of its glucose sensor products after identifying a manufacturing issue that can lead to falsely low glucose readings. The correction affects about ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback